MONTREAL,
Nov. 23, 2021 /CNW Telbec/ -
Theratechnologies Inc. ("Theratechnologies" or the
"Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies, today announced that it has filed a
preliminary short form base shelf prospectus with the securities
regulatory authorities of all the provinces of Canada and a corresponding shelf registration
statement with the United States Securities and Exchange Commission
(the "SEC") on Form F-10.
The filing is made for the purpose of restoring the
original financing capacity which was available to
Theratechnologies under its previous base shelf prospectus dated
November 15, 2019 expiring on December 15, 2021.
Once the shelf prospectus is cleared and the shelf
registration statement becomes effective, these filings will,
subject to securities regulatory requirements, provide for the
potential offering in Canada and the United
States of up to an aggregate of US $150,000,000 of
common shares, preferred shares, subscription receipts, warrants,
debt securities and units from time to time over a 25-month period
after Canadian securities regulatory authorities have issued a
receipt for the final short form base shelf prospectus. This shelf
prospectus is intended to give the Company the flexibility to take
advantage of financing opportunities when market conditions are
favourable. The terms of such future offerings, if any, will be
established at the time of such offerings. At the time any of the
securities covered by the shelf prospectus are offered for sale, a
prospectus supplement containing specific information about the
terms of any such offering will be filed with applicable Canadian
securities regulatory authorities and the SEC.
The shelf registration statement filed with the SEC
has not yet become effective. No securities may be sold, nor may
offers to buy be accepted, prior to the time the registration
statement becomes effective. This press release shall
not constitute an offer to sell or a solicitation of an offer to
buy, nor shall there be any offer, solicitation or sale of,
securities in any province, state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such
jurisdiction.
Renewal of ATM Facility
Upon the short form base shelf prospectus and shelf
registration statement becoming effective, the Company also intends
to file a prospectus supplement to the shelf registration statement
to renew its prospectus supplement of July 23, 2021
relating to its US $50,000,000 at-the-market ("ATM")
facility, which the Company intends on extending for the duration
of up to 25 months following the receipt of the Canadian
securities regulatory authorities for the base shelf prospectus.
The Company expects that the ATM sales agreement will be extended
in respect of the renewed prospectus supplement and corresponding
shelf registration statement.
A copy of the preliminary base shelf prospectus and
corresponding shelf registration statement is available on our
SEDAR profile at www.sedar.com or on EDGAR at www.sec.gov.
Alternatively, a copy of such documents is available upon request
by contacting the Company's Corporate Secretary at 2015 Peel
Street, Suite 1100, Montreal,
Québec, Canada, H3A 1T8,
telephone: (514) 336-7800.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies addressing unmet medical
needs. Further information about Theratechnologies is available on
the Company's website at www.theratech.com, on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov.
Forward-Looking Information
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended and forward-looking
information under applicable Canadian securities laws (such
forward-looking statements and forward-looking information are
collectively referred to herein as "forward-looking
statements"), that are based on our management's beliefs and
assumptions and on information currently available to our
management. You can identify forward-looking statements by terms
such as "may", "will", "should", "could", "would", "outlook",
"believe", "plan", "envisage", "anticipate", "expect" and
"estimate", or the negatives of these terms, or variations of them.
The forward-looking statements contained in this press release
include, but are not limited to, statements regarding the offer and
sale of securities, including the continuation of its ATM facility
and related sales agreement.
We refer potential investors to the "Risk Factors" section
of our annual information form dated February 24, 2021 available on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our
report on Form 40-F dated February 25,
2021 under Theratechnologies' public filings for additional
risks regarding the conduct of our business and Theratechnologies.
The reader is cautioned to consider these and other risks and
uncertainties carefully and not to put undue reliance on
forward-looking statements. Forward-looking statements reflect
current expectations regarding future events and speak only as of
the date of this press release and represent our expectations as of
that date.
We undertake no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise,
except as may be required by applicable law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theratechnologies-announces-renewal-of-shelf-prospectus-and-registration-statement-at-the-market-facility-to-be-extended-301430938.html
SOURCE Theratechnologies Inc.